794 related articles for article (PubMed ID: 34024158)
1. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
2. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
3. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
Mei M; Aldoss I; Marcucci G; Pullarkat V
Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
He H; Wen X; Zheng H
Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
[TBL] [Abstract][Full Text] [Related]
6. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
7. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.
Maiti A; Konopleva MY
Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA
Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549
[TBL] [Abstract][Full Text] [Related]
9. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
[No Abstract] [Full Text] [Related]
10. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax in acute myeloid leukemia - current and future directions.
Lachowiez C; DiNardo CD; Konopleva M
Leuk Lymphoma; 2020 Jun; 61(6):1313-1322. PubMed ID: 32031033
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
18. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract][Full Text] [Related]
19. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
Short NJ; Venugopal S; Qiao W; Kadia TM; Ravandi F; Macaron W; Dinardo CD; Daver N; Konopleva M; Borthakur G; Shpall EJ; Popat U; Champlin RE; Mehta R; Al-Atrash G; Oran B; Jabbour E; Garcia-Manero G; Issa GC; Montalban-Bravo G; Yilmaz M; Maiti A; Kantarjian H
J Hematol Oncol; 2022 Jan; 15(1):12. PubMed ID: 35093134
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Gangat N; Tefferi A
Blood Cancer J; 2020 Nov; 10(11):122. PubMed ID: 33230098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]